Massachusetts Financial Services Co. MA lessened its position in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 9.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 438,345 shares of the company's stock after selling 46,437 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.51% of HealthEquity worth $42,059,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the company. Holocene Advisors LP bought a new stake in HealthEquity in the third quarter worth $1,246,000. Pier Capital LLC purchased a new stake in shares of HealthEquity in the fourth quarter worth approximately $8,024,000. HighTower Advisors LLC lifted its stake in shares of HealthEquity by 4.8% during the 4th quarter. HighTower Advisors LLC now owns 95,075 shares of the company's stock worth $9,122,000 after acquiring an additional 4,370 shares during the last quarter. Geneva Capital Management LLC boosted its holdings in HealthEquity by 24.6% during the 4th quarter. Geneva Capital Management LLC now owns 1,048,903 shares of the company's stock valued at $100,642,000 after acquiring an additional 206,894 shares during the period. Finally, BNP Paribas Financial Markets grew its position in HealthEquity by 165.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 20,437 shares of the company's stock valued at $1,673,000 after acquiring an additional 12,745 shares during the last quarter. Institutional investors own 99.55% of the company's stock.
HealthEquity Stock Down 5.3 %
Shares of HQY stock traded down $4.38 during trading hours on Thursday, reaching $78.76. 178,997 shares of the company's stock were exchanged, compared to its average volume of 755,969. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.51. The company has a market cap of $6.81 billion, a price-to-earnings ratio of 72.37, a P/E/G ratio of 1.60 and a beta of 0.49. HealthEquity, Inc. has a fifty-two week low of $65.01 and a fifty-two week high of $115.59. The stock's 50 day moving average is $98.83 and its 200-day moving average is $96.26.
Analysts Set New Price Targets
A number of analysts have recently issued reports on the stock. Raymond James raised shares of HealthEquity from an "outperform" rating to a "strong-buy" rating and lowered their target price for the company from $120.00 to $115.00 in a research note on Tuesday, March 25th. Barrington Research reissued an "outperform" rating and issued a $112.00 price objective on shares of HealthEquity in a research report on Friday, March 14th. KeyCorp reduced their target price on shares of HealthEquity from $120.00 to $110.00 and set an "overweight" rating on the stock in a research report on Monday, March 24th. The Goldman Sachs Group lowered their price target on HealthEquity from $107.00 to $94.00 and set a "neutral" rating for the company in a report on Thursday, March 27th. Finally, Wells Fargo & Company raised their price objective on HealthEquity from $110.00 to $125.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, HealthEquity presently has an average rating of "Buy" and an average price target of $112.58.
Check Out Our Latest Analysis on HQY
Insiders Place Their Bets
In related news, EVP Michael Henry Fiore sold 8,881 shares of HealthEquity stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $78.26, for a total value of $695,027.06. Following the completion of the sale, the executive vice president now directly owns 56,655 shares in the company, valued at $4,433,820.30. This trade represents a 13.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Robert W. Selander sold 5,750 shares of the company's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $111.29, for a total transaction of $639,917.50. Following the transaction, the director now owns 78,219 shares in the company, valued at $8,704,992.51. The trade was a 6.85 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company's stock.
HealthEquity Company Profile
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
See Also
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
